LASA
SUPERGENERICS Q1FY21 PAT AT 5.37 CRS,
UP 437% YOY
UP 437% YOY
Lasa Supergenerics Limited, a vertically integrated group spanning the
entire animal and human healthcare value chain has announced its financial results for the first
quarter ended June 30th 2020 (Q1FY21)
·
Revenues
from operations stood at Rs. 54.60 crore as against Rs. 48.58 crore in Q4FY20
·
EBITDA of Rs. 12.20 crore as compared to Rs. 9.01
crore in Q4FY20
o
EBITDA margins at 22.34%
- PAT stood at Rs. 5.37 crore as compared to
Rs.2.61 crore in Q4FY20
·
EPS for Q1FY21 stood at Rs. 1.32
·
Revenues
from operations stood at Rs. 54.60 crore as against Rs. 38.98 crore in Q1FY20
·
EBITDA of Rs. 12.20 crore as compared to Rs. 5.06
crore in Q1FY20
o
EBITDA margins at 22.34% as against 12.98% in
Q1FY20
- PAT stood at Rs.5.37 crore as against a loss of
Rs.1.27 crore
·
EPS for Q1FY21 stood at Rs. 1.32 as compared to
Rs. 0.47 in Q1FY20
For first quarter ended
June 30th 2020
- Revenues from operations for the first quarter ended June 30th, 2020 (Q1FY21) stood
at Rs. 54.60 crore.
- The Company reported Earnings before Interest, Tax,
Depreciation and Amortization (EBITDA) of Rs. 12.20 crore in Q1FY21, as against
Rs 9.01 crore in Q4FY20; up 35.4%.
The Company’s EBITDA margin stood at 22.34% - The Company reported PAT of Rs. 5.37
crore for Q1FY21.The Company’s PAT margin stood at 9.84%
- Earnings per share (EPS) for the
quarter ended Q1FY21 stood at Rs 1.32
- The Finance cost reduced by 45% Q-o-Q from Rs. 2.29 crore in Q4FY20 to Rs. 1.29 crore in Q1FY21
Commenting on the performance, Dr. Omkar Herlekar, Chairman – Lasa
Supergenerics Limited, said,
“We have reported a good performance
in our business in Q1 FY21 despite significant disruptions and ambiguity in the
business environment. We are confident that the Company under its strong
leadership and planned strategies will navigate through these difficult times.
We have substantially brought down the debt.”
No comments:
Post a Comment